The FDA has issued a Public Health Advisory about reports of serious hepatotoxicity associated with the use of Ketek, an antiobiotic manufactured by Aventis Pharmaceuticals that is used to treat respiratory infections in patients over 18 years of age.

A report published in the Annals of Internal Medicine said three patients developed jaundice and abnormal liver function after being treated with Ketek. All three patients had previously been healthy with no history of liver problems. One patient recovered, one patient needed a liver transplant, and one patient died.

The FDA is investigating the issue and urges patients who may be affected to report the incidents to Medwatch.

Source: Food and Drug Administration Public Health Advisory, January 20, 2006.